← Back to Search

TetraGraph Monitoring for Neuromuscular Blockade Recovery

Waitlist Available
Led By J.Ross Renew, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age > or = 18 years old
Patients undergoing an elective surgical procedure requiring administration of rocuronium, and the use of a pulmonary artery catheter intraoperatively
Screening 3 weeks
Treatment Varies
Follow Up up to 1 hour postoperative
Awards & highlights

Study Summary

This trial is testing how long it takes for the medication used to relax muscles during surgery to wear off, and how this relates to heart function.

Who is the study for?
This trial is for adults over 18 who are having elective surgery needing muscle relaxation with rocuronium and a heart monitor (pulmonary artery catheter). They must be willing to consent. It's not for those with severe kidney or liver disease, surgeries involving an arm or leg in the sterile field, or people with conditions like stroke, nerve damage, Dupuytren contracture, or myasthenia gravis.Check my eligibility
What is being tested?
The study is testing TetraGraph to see how quickly patients recover from muscle relaxants used during surgery and how this recovery time relates to their heart function. The goal is to better understand the link between cardiac output and emergence from anesthesia.See study design
What are the potential side effects?
While specific side effects of TetraGraph monitoring aren't detailed here, typically such devices have minimal risks associated with them. However, potential side effects may relate more to the reversal of neuromuscular blockade rather than the device itself.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am 18 years old or older.
I am scheduled for surgery that will use rocuronium and monitor my heart with a special catheter.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 hour postoperative
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 hour postoperative for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Recovery time after administration of sugammadex and its correlation to cardiac output measure
Secondary outcome measures
Correlation of speed of recovery from neuromuscular blockade and age.

Trial Design

1Treatment groups
Experimental Treatment
Group I: TetraGraph monitoringExperimental Treatment1 Intervention
Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on either hand at a discretion of the anesthesiologist
First Studied
Drug Approval Stage
How many patients have taken this drug

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,205 Previous Clinical Trials
3,766,734 Total Patients Enrolled
2 Trials studying Neuromuscular Blockade
145 Patients Enrolled for Neuromuscular Blockade
J.Ross Renew, MDPrincipal InvestigatorMayo Clinic
3 Previous Clinical Trials
196 Total Patients Enrolled

Media Library

TetraGraph Clinical Trial Eligibility Overview. Trial Name: NCT04619225 — N/A
Neuromuscular Blockade Research Study Groups: TetraGraph monitoring
Neuromuscular Blockade Clinical Trial 2023: TetraGraph Highlights & Side Effects. Trial Name: NCT04619225 — N/A
TetraGraph 2023 Treatment Timeline for Medical Study. Trial Name: NCT04619225 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is patient enrollment for this research trial still available?

"According to clinicaltrials.gov, this medical trial has stopped enrolling patients since its last update on November 1st 2022. Despite not being able to take part in this study anymore, there are presently 5 other studies that can be taken advantage of by potential participants."

Answered by AI
~13 spots leftby Dec 2024